{"id":8912,"date":"2021-10-07T00:03:48","date_gmt":"2021-10-06T16:03:48","guid":{"rendered":"https:\/\/newsletter.sinica.edu.tw/en\/?p=8912"},"modified":"2024-03-13T09:19:58","modified_gmt":"2024-03-13T01:19:58","slug":"pdia4-regulates-%ce%b2-cell-pathogenesis-in-diabetes-molecular-mechanism-and-targeted-therapy","status":"publish","type":"post","link":"https:\/\/newsletter.sinica.edu.tw/en\/8912\/","title":{"rendered":"Pdia4 regulates \u03b2-cell pathogenesis in diabetes: molecular mechanism and targeted therapy"},"content":{"rendered":"
Diabetes has been incurable due to \u03b2-cell death and dysfunction in patients. \u03b2-cell preservation is thus emerging as a promising strategy to treat and reverse diabetes. A recent study by Dr. Wen-Chin Yang\u2019s research group at the Research Center of Agricultural Biotechnology, identified Pdia4, a key regulator of \u03b2-cell failure, as a novel therapeutic target of diabetes. Pre-clinical studies of a Pdia4 inhibitor, PS1, were completed and PS1 is now ready for the application of investigational drug to FDA and clinical trials. This study has been published in EMBO Molecular Medicine<\/em> on September, 2021.<\/p>\n